Study of Osimertinib in EGFR-mutant Non-small cell lung cancer patients with T790M-mutation detected by circulating tumour DNA

Trial Profile

Study of Osimertinib in EGFR-mutant Non-small cell lung cancer patients with T790M-mutation detected by circulating tumour DNA

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2017 New trial record
    • 18 Jan 2017 Results published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top